Clinical Trials Logo

Burkitt Lymphoma clinical trials

View clinical trials related to Burkitt Lymphoma.

Filter by:

NCT ID: NCT04166838 Recruiting - Clinical trials for B-cell Acute Lymphoblastic Leukemia (B-ALL)

The Clinical Study of CD19 UCAR-T Cells in Patients With B-cell Acute Lymphoblastic Leukemia (B-ALL)

Start date: November 8, 2019
Phase: Early Phase 1
Study type: Interventional

This is a single arm, open-label, single center, exploratory clinical study to evaluate the safety and efficacy of CD19 UCAR-T Cells in Patients With CD19+ B-cell acute lymphoblastic leukemia (B-ALL).

NCT ID: NCT03869619 Recruiting - Clinical trials for Follicular Lymphoma (FL)

REal World Data in LYmphoma and Survival in Adults

REALYSA
Start date: November 14, 2018
Phase:
Study type: Observational [Patient Registry]

REALYSA cohort is a population-based epidemiological platform in real-life for lymphomas designed to enrich prognostic data, by integrating together epidemiological, clinical and biological data. REALYSA is a platform perfectly set up to - Study prognostic factors using integrated epidemiological and biological data (genetics), to better characterize the determinants of refractoriness and relapse in patients with lymphoma, to follow the growing number of survivors and describe median to long-term sequela, second cancer, quality of life (QoL)… - Document treatment effectiveness in real life and observance - Address socio-economical questions

NCT ID: NCT03854994 Recruiting - Clinical trials for B-cell Acute Lymphoblastic Leukemia

CD19 CAR-T Cell Therapy for Relapsed/Refractory B-cell Lymphoma and B-cell Acute Lymphoblastic Leukemia

Start date: August 1, 2018
Phase: Phase 1
Study type: Interventional

The primary objective of this study is to evaluate the safety and clinical activity of anti-CD19 Chimeric Antigen Receptor T cells (KD-019 CAR-T)infusion in the treatment of relapsed/refractory B-cell Lymphoma and B-cell acute lymphoblastic leukemia (B-ALL).

NCT ID: NCT03825731 Recruiting - Clinical trials for B-cell Acute Lymphoblastic Leukemia

A Study of GC022 CAR-T Cell Immunotherapy for Relapsed or Refractory B- ALL

Start date: January 17, 2019
Phase: Early Phase 1
Study type: Interventional

The study is an early, open, single-centered trial. The aim of this study is to evaluate the safety and tolerance of GC022 CAR-T cell immunotherapy in relapsed or refractory B-ALL. The investigators plan to include 20 subjects to receive GC022 therapy.

NCT ID: NCT03810196 Recruiting - Clinical trials for Acute Myeloid Leukemia

CD45RA Depleted Peripheral Stem Cell Addback for Viral or Fungal Infections Post TCRαβ/CD19 Depleted HSCT

Start date: March 1, 2019
Phase: N/A
Study type: Interventional

The major morbidities of allogeneic hematopoietic stem cell transplant with non-human leukocyte antigen (HLA) matched siblings are graft vs host disease (GVHD) and life threatening infections. T depletion of the donor hematopoietic stem cell graft is effective in preventing GVHD, but immune reconstitution is slow, increasing the risk of infections. An addback of donor CD45RA (naive T cells) depleted cells may improve immune reconstitution and help decrease the risk of infections.

NCT ID: NCT03754764 Recruiting - Clinical trials for Relapsed B-cell Acute Lymphoblastic Leukemia After CD19 CAR-T ACI

A Feasibility and Safety Study of CD38 CAR-T Cell Immunotherapy for Relapsed B-cell Acute Lymphoblastic Leukemia After CD19 CAR-T Adoptive Cellular Immunotherapy

Start date: November 23, 2018
Phase: Phase 1/Phase 2
Study type: Interventional

CD19-directed CAR-T cell therapy has shown promising results for the treatment of relapsed or refractory B-cell malignancies; however, a subset of patients relapse due to the loss of CD19 in tumor cells. CD38 CAR-T cells can recognize and kill the CD19 negative malignant cells through recognition of CD38. This is a phase 1/2 study designed to determine the safety of the gene-edited specificity CD38 CAR-T cells and the feasibility of making enough to treat patients with relapsed B-cell acute lymphoblastic leukemia after CD19 CAR-T adoptive cellular immunotherapy.

NCT ID: NCT03671460 Recruiting - Clinical trials for B-cell Acute Lymphoblastic Leukemia

CD19 CAR-T Cells for Patients With Relapse and Refractory CD19+ B-ALL.

Start date: September 7, 2018
Phase: Phase 1
Study type: Interventional

This is a single center, single arm, open-lable phase 1 study to determine the safety and efficacy of CD19-CAR-T cells in patients with relapsed or refractory acute B-cell lymphoblastic leukemia (R/R B-ALL).

NCT ID: NCT03638206 Recruiting - Colorectal Cancer Clinical Trials

Autologous CAR-T/TCR-T Cell Immunotherapy for Malignancies

Start date: March 1, 2018
Phase: Phase 1/Phase 2
Study type: Interventional

This is a single arm, open-label, uni-center, phase I-II study to evaluate the safety and effectiveness of CAR-T/TCR-T cell immunotherapy in treating with different malignancies patients.

NCT ID: NCT03574168 Recruiting - Clinical trials for B-cell Acute Lymphoblastic Leukemia

CD19-CAR-T Cells in Patients With R/R B-ALL

Start date: July 20, 2018
Phase: Phase 1
Study type: Interventional

This is a single center, single arm, open-lable phase 1 study to determine the safety and efficacy of autologous or donor-derived allogeneic T cells expressing CD19 chimeric antigen receptors (referred to as "CD19-CAR-T cells") in patients with relapsed or refractory acute B-cell lymphoblastic leukemia (R/R B-ALL).

NCT ID: NCT03375619 Recruiting - Multiple Myeloma Clinical Trials

Long-term Follow-up Study of Patients Receiving CAR-T Cells

Start date: December 1, 2017
Phase:
Study type: Observational

This protocol is designed as a long-term follow-up study of participants who will receive CAR-T cells as part of a clinical trial at the Medical College of Wisconsin/ Froedtert Hospital. The clinical trials include the following: Phase 1 Study of CAR-20/19-T Cells in Patients with Relapsed Refractory B Cell Malignancies (NCT03019055); Phase I Trial of BCMA-TGF-BETA CAR-T Cells in Relapsed, Refractory Myeloma (NCT05976555); CAR20.19.22 T-cells in Relapsed, Refractory B-cell Malignancies (NCT05094206); LV20.19 CAR T-Cells in Combination With Pirtobrutinib for Relapsed, Refractory B-cell Malignancies (NCT05990465); CAR-20/19-T Cells in Patients With Relapsed Refractory B Cell Malignancies (NCT04186520)